Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

201954 citationsJournal Articlehybrid Open Access

Authors

Adam Cuker · Hospital of the University of Pennsylvania

Ann Bass · Urology San Antonio

Čongor Nadj

Mark Agius · Dignity Health

Brian Steingo

Krzysztof Selmaj · University of Warmia and Mazury in Olsztyn

Timothy Thoits · Spectrum Health

Alexandre Guerreiro

Abstract

Alemtuzumab-associated ITP occurs in approximately 2% of patients and is responsive to therapy. Careful monitoring is key for detection and favorable outcomes.

Topics & Keywords

Platelet Disorders and Treatments Autoimmune Bullous Skin Diseases Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Multiple Sclerosis Journal

Volume 26, Issue 1, pp. 48-56

DOI: 10.1177/1352458518816612

Field-Weighted Citation Impact: 6.69